(Q48245085)

9 February 2018

editorial

0 references

title

Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy? (English)

1 reference

9 February 2018

1 reference

1

Debbie L Shawcross

1 reference

9 February 2018

publication date

6 April 2015

1 reference

9 February 2018

Expert Review of Gastroenterology & Hepatology

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25846450%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25846450%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25846450%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

539-542

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25846450%20AND%20SRC:MED&resulttype=core&format=json

Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Ammonia and hepatic encephalopathy: the more things change, the more they remain the same.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Endotoxemia produces coma and brain swelling in bile duct ligated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Altered profile of human gut microbiome is associated with cirrhosis and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Alterations of the human gut microbiome in liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Ammonia impairs neutrophil phagocytic function in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257

Bacterial translocation of enteric organisms in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1035257